Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL.
Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, Chen A, Tan B, Cui J, Li D, Li Y, Qi Y, Wang D, Wu Y, Li D, Du B, Liu M, Huang H. · 2022
Read Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. by Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, Chen A, Tan B, Cui J, Li D, Li Y, Qi Y, Wang D, Wu Y, Li D, Du B, Liu M, Huang H. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9452296.txt.
Description
Zhang and co-authors report a non-viral way to build targeted CAR-T cells with CRISPR-Cas9. CAR-T therapy has shown strong results in blood cancers. Virus based production is slow, costly, and carries safety risks. Random gene insertion adds a further concern.
Their two-in-one method places the CAR gene at a set locus. One version put an anti-CD19 CAR into the AAVS1 safe-harbour site. A second type wove the CAR into the PD1 gene itself. That type cleared tumor cells better in mouse models. In a trial for relapsed B cell non-Hodgkin lymphoma, eight patients took part. The authors report complete remission in 87.5% of them. Responses lasted, with no serious adverse events seen.
Catalog record
| CREATOR | Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, Chen A, Tan B, Cui J, Li D, Li Y, Qi Y, Wang D, Wu Y, Li D, Du B, Liu M, Huang H. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 85 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |